drug
bimekizumab
Marketedupdated 3mo agoby UCB SA
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying bimekizumab
- phase3A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
- phase3A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- phase3A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- phase3A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
- phase1A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
- phase4Bimekizumab in Plaque Psoriasis
- phase3A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
News(5)
- AbbVie shares pressured as Q2 I&I beat falls below investor expectationsAbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.biospace · 11d ago
- UCB's stock slides despite Bimzelx revenue beating forecastsUCB's shares dropped Thursday on investor concern that the Belgian pharma could be overpromising on its full-year forecast, even as sales of its lead drug topped analysts' expectations. The company…endpoints · 12d ago
- Avalo shares spike on skin drug data; BioNTech to cut staffAvalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.biopharma_dive · 3mo ago
- Oruka surges as long-acting psoriasis drug shows early promiseA therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.biopharma_dive · 3mo ago
- STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studyA long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.stat · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that